Editorial: 2024 - A Promising Start for Regulatory Toxicology and Pharmacology
Regul Toxicol Pharmacol. 2024 Mar 20:105601. doi: 10.1016/j.yrtph.2024.105601. Online ahead of print.NO ABSTRACTPMID:38519011 | DOI:10.1016/j.yrtph.2024.105601 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 22, 2024 Category: Toxicology Authors: Martin van den Berg Lesa Aylward Source Type: research

Editorial: 2024 - A Promising Start for Regulatory Toxicology and Pharmacology
Regul Toxicol Pharmacol. 2024 Mar 20:105601. doi: 10.1016/j.yrtph.2024.105601. Online ahead of print.NO ABSTRACTPMID:38519011 | DOI:10.1016/j.yrtph.2024.105601 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 22, 2024 Category: Toxicology Authors: Martin van den Berg Lesa Aylward Source Type: research

Editorial: 2024 - A Promising Start for Regulatory Toxicology and Pharmacology
Regul Toxicol Pharmacol. 2024 Mar 20:105601. doi: 10.1016/j.yrtph.2024.105601. Online ahead of print.NO ABSTRACTPMID:38519011 | DOI:10.1016/j.yrtph.2024.105601 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 22, 2024 Category: Toxicology Authors: Martin van den Berg Lesa Aylward Source Type: research

Editorial: 2024 - A Promising Start for Regulatory Toxicology and Pharmacology
Regul Toxicol Pharmacol. 2024 Mar 20:105601. doi: 10.1016/j.yrtph.2024.105601. Online ahead of print.NO ABSTRACTPMID:38519011 | DOI:10.1016/j.yrtph.2024.105601 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 22, 2024 Category: Toxicology Authors: Martin van den Berg Lesa Aylward Source Type: research

Selectively addressing total risk avoidance for certain chemicals while overlooking others: The case of per-and-poly-fluoroalkyls
Regul Toxicol Pharmacol. 2024 Mar 17;149:105602. doi: 10.1016/j.yrtph.2024.105602. Online ahead of print.NO ABSTRACTPMID:38499056 | DOI:10.1016/j.yrtph.2024.105602 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 18, 2024 Category: Toxicology Authors: Alberto Boretti Source Type: research

Selectively addressing total risk avoidance for certain chemicals while overlooking others: The case of per-and-poly-fluoroalkyls
Regul Toxicol Pharmacol. 2024 Mar 17;149:105602. doi: 10.1016/j.yrtph.2024.105602. Online ahead of print.NO ABSTRACTPMID:38499056 | DOI:10.1016/j.yrtph.2024.105602 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 18, 2024 Category: Toxicology Authors: Alberto Boretti Source Type: research

Selectively addressing total risk avoidance for certain chemicals while overlooking others: The case of per-and-poly-fluoroalkyls
Regul Toxicol Pharmacol. 2024 Mar 16:105602. doi: 10.1016/j.yrtph.2024.105602. Online ahead of print.NO ABSTRACTPMID:38499056 | DOI:10.1016/j.yrtph.2024.105602 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 18, 2024 Category: Toxicology Authors: Alberto Boretti Source Type: research

Review of the standards of proof (of safety) for FDA regulated consumer products and how the generally recognized as safe criteria could be applied to cosmetics
Regul Toxicol Pharmacol. 2024 Mar 15:105603. doi: 10.1016/j.yrtph.2024.105603. Online ahead of print.ABSTRACTThe Modernization of Cosmetics Regulation Act of 2022 (MoCRA) amends the Food, Drug and Cosmetic Act (FDCA), elevating the standard of proof of safety (better known as a "safety standard") for cosmetics to the standard of a "reasonable certainty … [of] … safe."a standard equal to that of food ingredients. The standards of the proof of safety differ for various classes of FDA-regulated product categories (e.g., cosmetics, dietary supplements, food ingredients and food itself). This manuscript describes the variou...
Source: Regulatory Toxicology and Pharmacology : RTP - March 17, 2024 Category: Toxicology Authors: George A Burdock Source Type: research

Review of the standards of proof (of safety) for FDA regulated consumer products and how the generally recognized as safe criteria could be applied to cosmetics
Regul Toxicol Pharmacol. 2024 Mar 15:105603. doi: 10.1016/j.yrtph.2024.105603. Online ahead of print.ABSTRACTThe Modernization of Cosmetics Regulation Act of 2022 (MoCRA) amends the Food, Drug and Cosmetic Act (FDCA), elevating the standard of proof of safety (better known as a "safety standard") for cosmetics to the standard of a "reasonable certainty … [of] … safe."a standard equal to that of food ingredients. The standards of the proof of safety differ for various classes of FDA-regulated product categories (e.g., cosmetics, dietary supplements, food ingredients and food itself). This manuscript describes the variou...
Source: Regulatory Toxicology and Pharmacology : RTP - March 17, 2024 Category: Toxicology Authors: George A Burdock Source Type: research

The 2022 revised WHO TEFs for dioxins and dioxin-like chemicals: The importance of considering the use of species-specific information to determine relative effective potency for human-based risk assessment
Regul Toxicol Pharmacol. 2024 Mar 13:105599. doi: 10.1016/j.yrtph.2024.105599. Online ahead of print.NO ABSTRACTPMID:38490576 | DOI:10.1016/j.yrtph.2024.105599 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 15, 2024 Category: Toxicology Authors: David L Eaton Ted W Simon Norbert E Kaminski Gary H Perdew Daniel W Nebert Source Type: research

The 2022 revised WHO TEFs for dioxins and dioxin-like chemicals: The importance of considering the use of species-specific information to determine relative effective potency for human-based risk assessment
Regul Toxicol Pharmacol. 2024 Mar 13:105599. doi: 10.1016/j.yrtph.2024.105599. Online ahead of print.NO ABSTRACTPMID:38490576 | DOI:10.1016/j.yrtph.2024.105599 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 15, 2024 Category: Toxicology Authors: David L Eaton Ted W Simon Norbert E Kaminski Gary H Perdew Daniel W Nebert Source Type: research

WHO Toxic Equivalency Factors (TEFs) for dioxin like compounds, including studies supporting novel methodology for derivation of TEFs
Regul Toxicol Pharmacol. 2024 Mar 12:105600. doi: 10.1016/j.yrtph.2024.105600. Online ahead of print.NO ABSTRACTPMID:38484927 | DOI:10.1016/j.yrtph.2024.105600 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 14, 2024 Category: Toxicology Authors: Lesa L Aylward Source Type: research

WHO Toxic Equivalency Factors (TEFs) for dioxin like compounds, including studies supporting novel methodology for derivation of TEFs
Regul Toxicol Pharmacol. 2024 Mar 12:105600. doi: 10.1016/j.yrtph.2024.105600. Online ahead of print.NO ABSTRACTPMID:38484927 | DOI:10.1016/j.yrtph.2024.105600 (Source: Regulatory Toxicology and Pharmacology : RTP)
Source: Regulatory Toxicology and Pharmacology : RTP - March 14, 2024 Category: Toxicology Authors: Lesa L Aylward Source Type: research

Medical device report analyses from MAUDE: Device and patient outcomes, adverse events, and sex-based differential effects
We present an overview of >10 million MDRs received from 2011 to 2021. Approximately 92% of reporting issues represent medical device physical or functional failures, categorized from 1704 codes related to medical device integrity or function. ∼8% were coded adverse events (AEs). Patient outcomes are reported via 998 patient codes in 19 medical specialties (cardiovascular, orthopedic, etc.). ∼40% of patient reports indicated "no health consequences"; however, a small number of devices had consistently high AE reports. While overall reports did not exhibit a sex-based dichotomy, ∼9% of the reported AEs occurred mor...
Source: Regulatory Toxicology and Pharmacology : RTP - March 11, 2024 Category: Toxicology Authors: Tsung-Jen Liao Lynn Crosby Kevin Cross Minjun Chen Rosalie Elespuru Source Type: research

Medical device report analyses from MAUDE: Device and patient outcomes, adverse events, and sex-based differential effects
We present an overview of >10 million MDRs received from 2011 to 2021. Approximately 92% of reporting issues represent medical device physical or functional failures, categorized from 1704 codes related to medical device integrity or function. ∼8% were coded adverse events (AEs). Patient outcomes are reported via 998 patient codes in 19 medical specialties (cardiovascular, orthopedic, etc.). ∼40% of patient reports indicated "no health consequences"; however, a small number of devices had consistently high AE reports. While overall reports did not exhibit a sex-based dichotomy, ∼9% of the reported AEs occurred mor...
Source: Regulatory Toxicology and Pharmacology : RTP - March 11, 2024 Category: Toxicology Authors: Tsung-Jen Liao Lynn Crosby Kevin Cross Minjun Chen Rosalie Elespuru Source Type: research